The true impact of new targeted therapies for AML

Best Practice and Research in Clinical Haematology

Volumn 20, Issue 1, 2007, Pages 1-4

  Rowe, Jacob M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; ARSENIC; CEP 701; CHLORMETHINE; CLOFARABINE; DEOXYADENOSINE DERIVATIVE; GEMTUZUMAB OZOGAMICIN; HISTAMINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTERLEUKIN 2; MIDOSTAURIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; TANDUTINIB; TIPIFARNIB; UNCLASSIFIED DRUG; XL 99;

ACUTE GRANULOCYTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE EXPRESSION PROFILING; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA;

EID: 33847189143     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.11.003     Document Type: Editorial

References (4)

1. Huang M.E., Ye Y.C., Chen S.R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
2. Rowe J.M. Targeted therapy in leukemia - why and for whom?. In: Dicke K.A., and Keating A. (Eds). Stem cell and targeted therapy (2003), Carden & Jennings Publishing, Charlottesville, Virginia 3-11
3. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine 344 (2001) 1031-1036
4. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. The New England Journal of Medicine 350 (2004) 1605-1616